EIKN

← Markets

EIKNEikon Therapeutics, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Wed, Aug 26
6:30 AMglobenewswire.comEikon Therapeutics to Participate in Investor Conferences in September 2026
Sat, Aug 22
6:01 AMmarketbeat.comEikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Tue, Aug 18
3:15 PMYahooEikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Thu, Aug 13
3:02 PMYahooEikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Tue, Aug 11
6:30 AMYahooEikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
Mon, Jul 27
6:30 AMYahooEikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Mon, Jul 20
7:00 AMYahooEikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Thu, Jul 2
3:06 PMYahooIs Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
Thu, Jun 25
3:15 PMYahooEikon Therapeutics to Join the Russell 3000® Index
Mon, Jun 8
7:00 AMYahooEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
Sat, May 30
1:30 PMYahooEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Thu, May 21
4:05 PMYahooEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology